Synthasome Inc.

Synthasome was formed in 2003, with the objective of using the biotechnologies of tissue engineering and functional bioengineering to address unmet clinical needs, focusing on orthopaedic and musculoskeletal applications. A series of federally funded projects has lead the development of our first product, X-Repair™, that recently gained FDA 510k clearance and is now being used in clinical repair of rotator cuff injuries. Using our focused research and development team we continue to develop new and innovative orthobiologics products with applications in tendon, ligament, and articular cartilage repair and regeneration. Synthasome continues to use bioengineering approaches to address major clinical challenges.